Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors

This randomized phase II trial studies how well a health and recovery program works in increasing physical activity level in stage IA-IIIA endometrial cancer survivors. Health and recovery program which includes exercise counseling, Fitbit tracker, and phone or email/text communication may increase the level of physical activity in endometrial cancer survivors and promote and maintain behavior change at a lower cost.

Stanford is currently not accepting patients for this trial.

Intervention(s):

  • other: Communication Intervention
  • other: Counseling
  • other: Fitbit tracker
  • other: Quality-of-Life Assessment
  • other: Questionnaire Administration
  • behavioral: Telephone-Based Intervention

Eligibility


Inclusion Criteria:

   - Stage IA-IIIA endometrial cancer patients with pathology reviewed at Stanford

   - Patients must have undergone surgery as a part of their treatment for their
   endometrial cancer

   - At least 3 months post treatment

   - BMI > 25

   - Life expectancy of at least one year

   - Able to perform physical activity of walking

   - Possession of a computer and/or smart phone and/or smart tablet

   - Must be English or Spanish speaking

Exclusion Criteria:

   - Other active cancer

   - Receiving chemotherapy or other active treatment

   - BMI < 60

   - Diagnosis of uterine serous carcinoma or uterine sarcoma

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Melissa Usoz
650-723-8843
Not Recruiting

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.